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Abstract
Background: Coeliac disease is a chronic intestinal inflammatory disorder due to an aberrant immune response to
dietary gluten proteins in genetically predisposed individuals. Mucosal immune response through IgA secretion
constitutes a first line of defence responsible for neutralizing noxious antigens and pathogens. The aim of this
study was the characterization of the relationships between immunoglobulin-coated bacteria and bacterial
composition of faeces of coeliac disease (CD) patients, untreated and treated with a gluten-free diet (GFD) and
healthy controls.
Results: IgA-coated faecal bacterial levels were significantly lower in both untreated and treated CD patients than
in healthy controls. IgG and IgM-coated bacterial levels were also significantly lower in treated CD patients than in
untreated CD patients and controls. Gram-positive to Gram-negative bacteria ratio was significantly reduced in
both CD patients compared to controls. Bifidobacterium, Clostridium histolyticum, C. lituseburense and
Faecalibacterium prausnitzii group proportions were less abundant (P < 0.050) in untreated CD patients than in
healthy controls. Bacteroides-Prevotella group proportions were more abundant (P < 0.050) in untreated CD patients
than in controls. Levels of IgA coating the Bacteroides-Prevotella group were significantly reduced (P < 0.050) in
both CD patients in comparison with healthy controls.
Conclusions: In CD patients, reduced IgA-coated bacteria is associated with intestinal dysbiosis, which altogether
provide new insights into the possible relationships between the gut microbiota and the host defences in this
disorder.
Background
Coeliac disease (CD) is a chronic intestinal inflammatory
disorder triggered by the ingestion of gluten proteins in
susceptible individuals. The active phase of the disease
is characterized by a pro-inflammatory intestinal milieu
resulting from an aberrant immune response to dietary
gluten, along with increased epithelial permeability,
which may favour the traffic of luminal antigens to the
submucosa [1]. In CD patients, gliadin peptides can acti-
vate either an adaptive immune response dominated by
Th1 pro-inflammatory cytokines (e.g. IFN-g) within the
mucosa or an innate immune response mediated by
IL-15, both of which lead to epithelial cell killing [2].
Gliadin also activates the zonulin pathway leading to an
increase in intestinal permeability [1].
The aetiology of CD is multifactorial, involving genetic
and environmental factors. This disorder is strongly
associated to the human leukocyte antigen genes (HLA).
Approximately 95% of the patients inherit the alleles
encoding for the HLA-DQ2 and HLA-DQ8 molecules,
but only a small percentage develops CD [3]. Studies of
identical twins have also shown that one twin did not
develop CD in 25% of the cases studied [4], supporting
the role played by environmental factors in the aetiology
of this disorder. However, the elements leading to a
breakdown in oral tolerance to gluten in predisposed
individuals are as yet unknown. The gut microbiota con-
stitutes a complex pool of antigens separated from the
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epithelial cells. In this mucosal immune system IgA con-
stitutes a first line of defence responsible for neutrali-
zing noxious antigens and pathogens [5]. In fact,
malfunction of immune cellso fP e y e rP a t c h e si np r o -
duction of secretory IgA has been considered a risk fac-
tor for CD development [6]. It has also been speculated
that a transient infection could promote inflammation
and increase permeability of the mucosa to antigens by
activating a Th1 response with secretion of IFN-g,t h e
major pro-inflammatory cytokine in CD patients [7,8].
Moreover, alterations in the intestinal microbiota com-
p o s i t i o no fC Dc h i l d r e ni nc o m p a r i s o nw i t ht h a to f
healthy controls, as well as changes in the metabolites
derived from the gut microbial activity have been
recently reported [9-12]. Nevertheless, the possible rela-
tionship between the gut microbiota composition and
the first line of immune defence in CD patients remains
uncharacterized.
Herein, the percentage of immunoglobulin-coated bac-
teria and the faecal microbiota composition of children
with CD (untreated and treated with a gluten-free diet
[GFD]) and controls were evaluated, thus shedding light
on the possible associations between the intestinal bac-
teria and the host defences in this disorder.
Results
Immunoglobulin-coated bacteria of faeces
from CD patients
Immunoglobulin-coated bacteria were quantified in
faeces of both CD patient groups and healthy controls
to establish whether CD could be associated with gut
barrier defects or abnormal immune responses to the
intestinal microbiota (Figure 1). Overall, higher percen-
tages of IgA, IgM and IgG-coated bacteria were detected
in healthy controls than in both CD patient groups. The
proportions of IgA-coated bacteria were significantly
lower in untreated (P =0 . 0 1 8 )a n dt r e a t e dC Dp a t i e n t s
(P = 0.003) than in healthy controls. The proportions of
IgG and IgM-coated bacteria were also significantly
lower in treated CD patients than in controls (P <0 . 0 0 1
and P = 0.003, respectively) and untreated CD patients
(P <0 . 0 0 1a n dP = 0.009, respectively). The levels of
IgG were also slightly lower in untreated CD patients
than in healthy controls but the differences were not
significant (P = 0.069).
General microbiota composition of faeces from CD
patients
The composition of faecal microbiota of CD patients
treated and untreated with a GFD and healthy controls
was characterized by using oligonucleotide probes target-
ing the main bacterial groups colonizing the human gut
(Figure 2; Table 1). The three groups of children under
study were matched by age considering the variability of
the composition of human microbiota during the first
years of life. Total Gram-positive bacterial populations
were the highest in healthy controls and the lowest in
untreated CD patients, while it reached intermediate
values in treated CD. These differences were statistically
significant (P = 0.004) between untreated CD patients
and controls (Figure 2A). Gram-positive bacterial levels
did not normalize completely after a long-term GFD in
treated CD patients, although the differences did not
reach statistical significance (P = 0.203) when compared
with controls. Total Gram-negative bacteria reached
similar values (ranging from 27.5 to 32.7%) in faeces
from the three population groups (P = 0.323-0.650;
Figure 2A). The ratio of total Gram-positive to Gram-
negative bacteria was the highest in healthy controls and
significantly reduced in treated CD patients (P = 0.045)
and even more in untreated CD patients (P = 0.006).
Figure 1 Immunoglobulin-coated bacteria in faecal samples from untreated (white bars) and treated CD patients (grey bars) and
healthy controls (black bars) as assessed by FCM. Panel A, IgA-coated bacteria; Panel B, IgG-coated bacteria; Panel C, IgM-coated bacteria.
Date are expressed as a proportion of bacterial cells labelled with FITC-F(ab’)2 antihuman IgA, IgG or IgM to total cell population hybridising
with propidium iodine. Median values and ranges are given. *Significant differences were established at P < 0.050 by applying the Mann-
Whitney U-test.
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patients
The specific group and species composition of the faecal
microbiota of CD patients with untreated and treated CD
and healthy controls are shown in Table 1. The highest
differences in the relative abundance of specific bacterial
groups were found between untreated CD patients and
healthy controls, while treated CD patients generally
showed intermediate values. Bifidobacterium proportions
were significantly lower in untreated CD patients than in
healthy controls (P = 0.009), while treated CD patients
displayed intermediate values. Similarly, the relative abun-
dance of bacteria belonging to C. histolyticum, C. lituse-
burense and F. prausnitzii groups proved to be
significantly lower in untreated CD patients than in
healthy subjects (P = 0.031, P =0 . 0 2 4a n dP = 0.045,
respectively), whereas treated CD patients showed inter-
mediate values. The Bacteroides-Prevotella group propor-
tions were significantly more abundant in untreated CD
patients than in healthy controls (P =0 . 0 3 3 ) .Escherichia
coli, Staphylococcus, Lactobacillus-Enterococcus and sul-
phate-reducing bacteria reached similar proportions in the
three groups of children regardless of their health status.
Immunoglobulin A coating specific bacterial groups in
faeces from CD patients
Of the total bacteria, the percentage of IgA coating
Bacteroides-Prevotella group was significantly higher in
Figure 2 General composition of the faecal microbiota of untreated (white bars) and treated CD patients (grey bars) and healthy
controls (black bars) as assessed by FISH and FCM. Data are expressed as proportions of bacterial cells hybridising with group-specific
probes to total bacteria hybridising with EUB probe 338. Total Gram-negative bacteria and Gram-positive bacteria were calculated by adding the
relative proportions of the corresponding groups detected by using group-specific probes. Median values and ranges are given. *Significant
differences were established at P < 0.05 by applying the Mann-Whitney U-test.
Table 1 Faecal microbiota composition of untreated and treated CD patients and age-matched healthy controls
assessed by FISH and FCM
Microbial groups Specific group-probed cells/EUB-388 cells (%)
1
Untreated CD (n = 24) Treated CD (n = 18) Control (n = 20)
Median Range Median Range Median Range
Bifidobacterium 7.73 22.08-3.27 9.20 33.82-1.58 12.54 33.68-6.94
C. histolyticum 5.26 27.61-0.71 9.41 39.60-2.95 11.61 35.69-0.16
C. lituseburense 3.23 27.24-0.17 4.41 29.85-0.28 6.83 19.56-1.05
Lactobacillus-Enterococcus 1.94 10.93-0.14 1.12 9.30-0.22 1.76 16.47-0.25
Staphylococcus 10.36 37.38-0.89 16.49 42.91-0.51 18.04 41.32-0.19
Bacteroides-Prevotella 3.54 20.85-0.80 2.61 15.07-0.25 2.32 5.53-0.33
E. coli 5.20 23.42-0.48 6.39 28.77-0.55 7.32 28.26-1.10
F. prausnitzii 6.03 37.50-1.07 11.09 37.84-2.95 13.88 37.08-2.32
Sulphate-reducing bacteria 9.58 38.02-2.84 9.82 41.74-2.09 10.02 36.92-2.92
1 Data were expressed as proportions of bacterial cells hybridising with group-specific probes to total bacteria hybridising with EUB probe 338.
* Statistical significant differences were calculated using the Mann-Whitney U-test and established at P < 0.050.
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(P = 0.014) and treated CD patients (P = 0.019). A
10.93% (6.13-20.13) of Bacteroides-Prevotella group
from healthy patients was IgA-coated, while a 4.24%
(4.68-6.54) and a 4.97% (0.88-8.34) was IgA-coated in
untreated and treated CD patients, respectively.
Accordingly, within the Bacteroides-Prevotella popula-
tion, the percentage which was coated with IgA was
significantly higher in healthy controls (69.02%; 40.54-
81.61) than in untreated CD (P = 0.033) (25.42%; 7.09-
55.09), while no differences were detected with treated
CD patients. No differences were found in the propor-
tion of IgA coating the Bifidobacterium group between
CD patients and healthy controls. The percentage of
IgA-coated Bifidobacterium was higher (P <0 . 0 5 )t h a n
that of IgA-coated Bacteroides-Prevotella in all groups
of children.
Discussion
This study has characterized faecal microbiology and
immunoglobulin-associated features in active and non-
active stages of CD in children and in age-matched con-
trols with an aim to furthering our understanding of the
interplay between the gut microbiota and the host
defences in this disorder. Immunoglobulin secretions
constitute a primary line of defence of the mucosal sur-
face against noxious antigens and pathogens, and con-
tribute to the intestinal homeostasis preventing clinical
inflammation. The colon predominantly harbours IgA-
secreting plasma cells (90%); moreover, 4% cells secrete
IgG and 6% cells secrete IgM. A considerable percen-
tage of faecal bacteria was coated with IgA (14.71%) in
healthy individuals, whereas a lower bacterial percentage
was coated with IgG and IgM, and a similar trend was
observed in CD patients, as reported in other subjects
[13]. Significantly lower levels of IgA-coated bacteria
were detected in faecal samples of untreated and treated
CD patients when compared to healthy controls. It can
be speculate that these results could reflect the exis-
tence of a barrier defect in CD patients, which fails to
stabilise the gut microbiota and prevent the host from
the invasion of harmful antigens and pathogens. In
addition, treated CD patients showed lower levels of
IgG and IgM coated bacteria. In contrast, IBD patients
displayed a higher percentage of immunoglobulin-
coated faecal bacteria in active disease and shortly after
remission, supporting the concept that the mucosal tol-
erance to the gut microbiota is deregulated in these
patients [5].
A remarkable reduction in Gram-positive bacterial
populations was characteristic of the active phase of
the disease while its abundance was partially restored
in patients under a GFD. In addition, a reduction in
the ratio of Gram-positive to Gram-negative bacteria
was found in the patients regardless of the phase of
the disorder. The levels of total Gram-positive bacteria
were also lower in duodenal biopsies of patients with
active and inactive CD than in controls, while the pro-
portions of total Gram-negative bacteria were over-
represented particularly in biopsies of active CD
patients [12]. Therefore, the results obtained first in
biopsies and now in faeces from children of the same
age confirm similar structural changes in the composi-
tion of the gut microbiota associated with CD. The
reductions in beneficial Gram-positive bacteria could
favour the residence and interactions of harmful
Gram-negative bacteria within the mucosal surface of
CD patients, thereby contributing to loss of gluten tol-
erance. Antigenic structures of Gram-negative bacteria
such as flagellins and lipopolysaccharides have been
related to the inflammatory responses and pathogen-
esis of IBD [14]. Shifts in the intestinal microbiota,
characterized by increases in pro-inflammatory Gram-
negative bacteria, have also been shown to aggravate
murine colitis via activation of acute inflammation
through Toll-like receptor signalling [15].
Of the specific bacterial groups analysed, the Bifido-
bacterium population was significantly reduced in fae-
cal samples of untreated CD patients as compared
with controls. Bifidobacterium populations significantly
decreased or slightly decreased in faeces of IBD
patients, as detected by cultural techniques and real
time PCR, respectively [16]. The benefits obtained by
administering some Bifidobacterium s t r a i n sa sp a r to f
probiotic mixtures or symbiotics (probiotics combined
with prebiotics) in ulcerative colitis and pouchitis also
support the notion that this bacterial group is relevant
to IBD [17]. C .h i s t o l y t i c u m ,C .l i t u s e b u r e n s eand
F. prausnitzii groups were present in higher propor-
tions in healthy individuals than in CD patients; parti-
cularly, the abundance of C. histolyticum followed a
similar trend to that found in biopsy specimens
although the differences were not significant [12].
C. coccoides and C. leptum groups were lower in faeces
of Crohn’s disease and ulcerative colitis patients when
determined by real-time PCR [16]. A depletion of
F. prausnitzii population in faecal mucus of active
Crohn’s disease, but not in ulcerative colitis, has also
been detected [18]. Comparative analysis of biopsy and
faecal samples of IBD patients, based on genomic-
library sequencing analysis,a l s os h o w e dr e d u c t i o n si n
Firmicutes belonging to the class Clostridia in active
and in remission Crohn’s disease patients as compared
to healthy or ulcerative colitis groups [19,20]. Although
some studies are controversial, it appears that the pre-
sence of certain Clostridium groups and F. prausnitzii
is deficient in luminal or mucosa-associated microbio-
tas of Crohn’s disease and probably of CD patients too.
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butyrate, which is an important energy source for colo-
nocytes and exerts anti-inflammatory effects, for
instance by inhibiting the lipopolysaccharide-induced
cytokine response [19]. In contrast, the Bacteroides-
Prevotella group was found in higher proportions in
untreated CD patients than in controls, as previously
detected in duodenal biopsy specimens [12]. Associa-
tions between the phylum Bacteroidetes and Crohn’s
disease were revealed by comparative bacteriological
analysis of biopsy specimens of Crohn’s disease and
ulcerative colitis patients by denaturing gradient gel
electrophoresis (DGGE) [17]. Similar comparative
analyses of the mucosal-associated microbiota by geno-
mic-library sequencing of 16S rRNA genes showed
increases in Proteobacteria and Bacteroidetes, particu-
larly in Crohn’s disease patients [19]. Nevertheless, a
recent study reported that B. fragilis and B. vulgatus
were found at lower levels in faeces of IBD patients
when compared to those of healthy controls [16].
As Bacteroides and Bifidobacterium seem to be
possible relevant bacterial groups to CD, specific per-
centages of IgA coating these two bacterial groups
were also determined. Interestingly, the proportions of
IgA-coated Bacteroides-Prevotella were higher in
healthy individuals than in treated and untreated CD
patients, suggesting an increased defensive response of
the gut mucosal immune system to this bacterial
group in healthy children than in CD patients. The
combination of an increased proportion of Bacteroides-
Prevotella group in faecal samples of CD patients
together with a weaker defensive IgA response could
explain the recurrent relationship found between Bac-
teroides and inflamed gut mucosa in CD [12,21],
although more direct evidence is needed to confirm
this hypothesis. A higher percentage of IgA-coated
Bifidobacterium than IgA-coated Bacteroides-Prevotella
was detected in all groups of children, similarly to
other studies [5]. This could be a consequence of an
increased interaction between the gut mucosal immune
system and this bacterial group [5], which contributes
to mucosal tolerance towards high gut Bifidobacterium
concentrations.
Conclusions
This study confirms that in CD patients there is an
alteration in the type of faecal immunoglobulin-coated
bacteria that is associated with a shift in the structure
of the microbiota. In particular, increases in the rela-
tive abundance of Bacteroides-Prevotella group are par-
alleled to reductions in the IgA coating this group,
which could suggest a reduction of of the host
defences against this bacterial group. However, the
possible clinical consequences of these finding are still
unknown and their elucidation would require further
investigations.
Methods
Subjects
Altogether 62 children were included in the study:
24 untreated CD patients (mean age 5.5 years, range
2.1-12.0 years) on a normal-gluten containing diet,
showing clinical symptoms and signs of the disease,
positive CD serology markers (anti-gliadin antibodies
and anti-transglutaminase antibodies) and signs of
severe enteropathy by duodenal biopsy examination
classified as type 3 according to Marsh classification of
CD; 18 treated CD patients (mean age 5.5 years, range
1.0-12.3 years) on a gluten-free diet for at least 2 years,
without symptoms of the disease, showing negative CD
serology markers and normal mucosa architecture; and
20 healthy children (mean age 5.3 years, range 1.8-10.8
years) without known gluten intolerance.
None of the children were treated with antibiotics at
least 1 month before to the faecal sampling. The study
was conducted in accordance with the ethical rules of
the Helsinki Declaration (Hong Kong revision, Septem-
ber 1989), following the EEC Good Clinical Practice
guidelines (document 111/3976/88 of July 1990) and
current Spanish law, which regulates clinical research in
humans (Royal Decree 561/1993 regarding clinical
trials). Children were enrolled in the study after written
informed consent obtained from their parents.
Faecal sample preparation
Faeces from the three groups of children were collected
in sterile plastic boxes, frozen immediately after collec-
tion at -20°C, and stored until analysed. Faeces were
diluted 1: 10 (w/v) in PBS (pH 7.2) and homogenized in
a Lab Blender 400 stomacher (Seward Medical London,
UK) for 5 min. After low-speed centrifugation (2,000 g,
2 min), the supernatant was collected. For bacterial
quantification, cells were fixed by adding 4% paraformal-
dehyde solution (Sigma, St Louis, MO) and incubated
overnight at 4°C. After fixation, bacteria were washed
twice in PBS by centrifugation (13,400 g for 5 min).
Finally, cell pellets were suspended in a PBS/ethanol
mixture (1:1) and stored at -80°C until analyzed as pre-
viously described [12].
Immunoglobulin-coated bacterial analysis
Bacterial cells from 20 μl of the supernatant obtained
after low-speed centrifugation were collected (12,000
rpm for 5 min). The pellet was resuspended in 60 μl1 %
(w/v) BSA/PBS, containing 1% (v/v) FITC-labelled F(ab’)
2 antihuman IgA, IgG or IgM (CALTAG Laboratories,
Burlingame, CA). Another aliquot of each sample was
pelleted and resuspended in 60 μl1 %( w / v )B S A / P B S
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sions were washed twice with PBS. Bacterial pellet was
finally resuspended in 500 μl PBS and mixed with 20 μl
propidium iodine (100 mg l
-1) to label total bacteria
before flow cytometry detection [5]. To determine the
percentage of IgA coating the Bacteroides-Prevotella and
Bifidobacterium groups, the hybridised bacteria were
resuspended in 60 μl 1% (w/v) BSA/PBS, containing 1%
(v/v) FITC-labelled F(ab’)2 antihuman IgA (CALTAG
Laboratories, Burlingame, CA). After 30 min incubation,
suspensions were washed twice with cold PBS, stored at
4°C in the dark and analysed within few hours, as pre-
viously described [5].
Microbiological analysis by fluorescent in situ
hybridisation
The bacterial groups present in faeces were quantified
by fluorescent in situ hybridization (FISH) using
group-specific probes (MOLBIOL, Berlin, Germany).
The specific probes and controls used in this study, as
well as the hybridization conditions, are shown in
Table 2. In the case of E. coli a 50°C hybridization
temperature was used. The EUB 338 probe, targeting a
conserved region within the bacterial domain, was
used as a positive control [22] and the NON 338
probe was used as a negative control to eliminate
background fluorescence [23]. Control probes were
covalently linked at their 5’ end either to indocyanine
dye Cy3 or to fluorescein isothiocyanate (FITC). Speci-
fic cell enumeration was performed by combining each
of the group-specific FITC-probes with the EUB 338-
Cy3 probe as previously described [12]. Briefly, fixed
cell suspensions were incubated in the hybridization
solution (10 mmol l
-1 Tris-HCl, 0.9 mol l
-1 NaCl pH
8.0 and 10% SDS) containing 4 ng μl
-1 of each fluores-
cent probe at appropriate temperatures, overnight.
Then, hybridised cells were pelleted by centrifugation
(12,000 rpm for 5 min) and resuspended in 500 μlP B S
solution for flow-cytometry analysis.
Flow cytometry
Flow cytometry detections were performed using an
EPICS® XL-MCL flow cytometer (Beckman Coulter, Flor-
ida, USA) as previously described [12]. This instrument is
equipped with two light scatter detectors that measure for-
ward (FSC) and side scatter (SSC) and fluorescence detec-
tors that detect appropriately filtered light at green (FL1,
525 nm) and red-orange (FL3, 620 nm) wavelengths. The
event rate was kept at the lowest setting (200-300 events
per second) to avoid cell coincidence. A total of 15,000
events were recorded in a list mode file and analyzed with
the System II V.3 software (Beckman Coulter). The pro-
portion of each bacterial group was expressed as a ratio of
cells hybridising with the FITC-labelled specific probe to
cells hybridising with the universal EUB 338-Cy3 probe
[12]. Total Gram-negative bacteria and Gram-positive bac-
teria were calculated by adding the relative proportions (%
specific group/EUB) of the corresponding groups. Immu-
noglobulin-coated bacteria was expressed as a ratio of bac-
terial cells labelled with FITC-labelled F(ab’)2 antihuman
IgA, IgG or IgM to the bacterial cell populations hybridis-
ing with either propidium iodine, EUB338 probe, Bacter-
oides-Prevotella group-specific probe or Bifidobacterium
group-specific probe [5].
Statistical analyses
Statistical analyses were done using the SPSS 11.0 soft-
ware (SPSS Inc, Chicago, IL, USA). Due to non-normal
distribution, microbial and immunoglobulin coating bac-
terial data are expressed as medians and ranges (maxi-
mum-minimum values). The differences between two
groups of samples were determined by applying the
Mann-Whitney U test. In every case, a P-value < 0.05
was considered statistically significant.
Abbreviations
CD: Coeliac disease; Ig: Immunoglobulin; HLA: Human Leukocyte Antigen;
FCM: Flow cytometry; FISH: Fluorescence in situ hybridization; GFD: Gluten-
free diet; IBD: Inflammatory bowel disease.
Table 2 Oligonucleotide probes and hybridisation conditions used in the analysis of faecal bacteria by FISH and FCM
Probe Target Bacterial group Sequence (5’-3’) Hybridisation Conditions (°C) References
Eub 338 Domain bacteria GCT GCC TCC CGT AGG AGT 50 [13]
Non 338 Negative control ACA TCC TAC GGG AGG C 50 [14]
Bif 164 Bifidobacterium CAT CCG GCA TTA CCA CCC 50 [24]
Lab 158 Lactobacillus/Enterococcus GGT ATT AGC A(C/T)C TGT TTC CA 45 [25]
Bac 303 Bacteroides/Prevotella CCA ATG TGG GGG ACC TT 45 [26]
Ecol 1513 Escherichia coli CAC CGT AGT GCC TCG TCA TCA 50 [27]
Chis 150 Clostridium histolyticum TTA TGC GGT ATT AAT CT(C/T) CCT TT 50 [28]
C Lis 135 Clostridium lituseburense GTT ATC CGT GTG TAC AGG G 50 [28]
FPrau 645 Faecalibacterium prausnitzii CCT CTG CAC TAC TCA AGA AAA AC 50 [29]
SRB 687 Sulphate-reducing bacteria TAC GGA TTT CAC TCC T 50 [30]
STA Staphylococcus TCC TCC ATA TCT CTG CGC 50 [31]
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